Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Multiple Myeloma

 

SNS01-T for Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma (2669)
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma or Diffuse Large B Cell Lymphoma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma , Lymphoma;    Status: Recruiting;   Study ID: NCT01435720

Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01503242

Lenalidomide + Bortezomib + Dexamethasone for Multiple Myeloma (2477)
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01208662

Carfilzomib and Pomalidomide With Dexamethasone for Relapsed or Refractory Multiple Myeloma (2512)
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Investigator: William Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01464034

Carfilzomib w/ Cyclophosphamide and Dexamethasone pre STM for Multiple Myeloma (2599)
A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone Prior to Autologous Stem Cell Transplant in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Closed;   Study ID: NCT01660750

PCI-32765 for Relapsed or Relapsed and Refractory Multiple Myeloma (2694)
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01478581

ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone for Relapsed-and-Refractory Multiple Myeloma (9056)
A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma (ACE-MM-102)

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01997840

Oprozomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma (2723)
Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01881789

SAR650984 for CD38+ Hematological Malignancies
Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected CD38+ Hematological Malignancies

Investigator: William Bensinger, MD;   Conditions: Hematological Malignancies;    Status: Recruiting;   Study ID: NCT01084252

ACY-1215 in Combination With Lenalidomide, and Dexamethasone for Multiple Myeloma
A Phase 1, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01583283

Carfilzomib + Melphalan/Prednisone for Newly Diagnosed Multiple Myeloma (CLARION Study)
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Investigator: Edward Libby, MD;   Conditions: Multiple Myeloma;    Status: Pending;   Study ID: NCT01818752